| Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. | |
| | |
MedLine Citation:
|
PMID: 17574976 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Detection of residual tissue after thyroidectomy for papillary or follicular thyroid carcinoma may be performed using diagnostic imaging with either (123)I or (131)I. The former is often preferred to avoid "stunning"-defined as a reduction in uptake of the therapeutic dose of (131)I caused by some form of cell damage from the diagnostic dosage of the radionuclide. Stunning could potentially reduce the therapeutic efficacy of (131)I given to ablate a post-thyroidectomy remnant. This study examines the outcomes of ablative (131)I therapy after diagnostic studies with either (123)I or (131)I to determine if the diagnostic dosages of these radionuclides used in our Thyroid Cancer Center reduce the efficacy of (131)I given for remnant ablation. METHODS: Fifty patients with nonmetastatic papillary or follicular carcinoma of the thyroid received total thyroidectomy; this was followed by thyroid hormone withdrawal to achieve a serum thyroid-stimulating hormone level in excess of 30 microIU/mL. They were divided prospectively into 2 groups. Group 1 had diagnostic imaging with 14.8 MBq of (123)I followed by thyroid remnant ablation with 3.7 GBq of (131)I. Group 2 had empiric ablation with the same 3.7-GBq (131)I dosage, but the preceding diagnostic scan was performed with 74 MBq of (131)I. Comparisons of equivalence of the 2 population samples and of the post-ablation outcomes were evaluated by chi(2) analysis. Successful ablation required a negative follow-up thyroid scan 6-8 mo after ablation and also an undetectable serum thyroglobulin level in the absence of antithyroglobulin antibodies. RESULTS: There was no significant difference between the 2 groups demographically, in tumor burden or stage, or in the post-thyroidectomy ablation rate (group 1, 81%; group 2, 74%; P > 0.05). CONCLUSION: If thyroid remnant stunning occurs due to 74 MBq (131)I used as a diagnostic agent before (131)I ablation, it has no significant clinical correlate, as it yields the same ablation rate as that which occurs after 14.8 MBq of (123)I used for imaging. |
| | |
Authors:
|
Edward B Silberstein |
Related Documents
:
|
18585556 - Risk factors for well-differentiated thyroid carcinoma in patients with thyroid nodular... 7431686 - Secondary carcinoma of the thyroid gland. 15251656 - Metastatic breast carcinoma mimicking primary thyroid neoplasm in young women. 1196576 - Cancer of the thyroid following radium application to the neck. 23589996 - Expression of e-cadherin in primary endometrial carcinomas: clinicopathological and imm... 22045766 - Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. |
Publication Detail:
|
Type: Comparative Study; Journal Article Date: 2007-06-15 |
Journal Detail:
|
Title: Journal of nuclear medicine : official publication, Society of Nuclear Medicine Volume: 48 ISSN: 0161-5505 ISO Abbreviation: J. Nucl. Med. Publication Date: 2007 Jul |
Date Detail:
|
Created Date: 2007-07-03 Completed Date: 2007-08-27 Revised Date: 2008-02-29 |
Medline Journal Info:
|
Nlm Unique ID: 0217410 Medline TA: J Nucl Med Country: United States |
Other Details:
|
Languages: eng Pagination: 1043-6 Citation Subset: IM |
Affiliation:
|
Division of Nuclear Medicine, Department of Radiology, University of Cincinnati Medical Center, Cincinnati, Ohio 45219, USA. silbereb@healthall.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma, Follicular
/
radionuclide imaging*,
radiotherapy Adult Carcinoma, Papillary / radionuclide imaging*, radiotherapy Female Humans Iodine Radioisotopes / diagnostic use, therapeutic use* Male Middle Aged Radiopharmaceuticals / diagnostic use, therapeutic use* Thyroid Hormones / blood Thyroid Neoplasms / radionuclide imaging*, radiotherapy Thyroidectomy Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Iodine Radioisotopes; 0/Radiopharmaceuticals; 0/Thyroid Hormones |
| Comments/Corrections | |
Comment In:
|
J Nucl Med. 2008 Jan;49(1):166; author reply 166-7
[PMID:
18165699
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) i...
Next Document: Disulfiram inhibits defluorination of (18)F-FCWAY, reduces bone radioactivity, and enhances visualiz...